The seminar will delve into the definition, epidemiology, and phenotypes of cardiogenic shock, providing a foundational understanding of its various manifestations and prevalence. Attendees will also gain insights into the latest advancements in medical therapy and explore mechanical circulatory support options and the pivotal role of the care team.

At the conclusion of this activity, learners will be better able to: 

• Review the clinical trial data and current use of medical therapy in the management of cardiogenic shock
• Evaluate the role of acute mechanical support in the management of patients with cardiogenic shock
• Discuss the importance of the cardiogenic shock team and strategies to optimize patient outcomes

This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.

• Elizabeth Ashley Hardin, MD
• Katie Ginder, MSN, APRN, AGACNP-BC
• Anas Jawaid, MD
• Benjamin Wang, PharmD, BCCP

Faculty Disclosures
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

• Ashley Hardin
• Katie Ginder, MSN, APRN, AGACNP-BC
• Benjamin Wang, PharmD, BCCP 
• Shauna Wheeler, MS (CE Reviewer)

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Freny Vaghaiwalla Mody, MD – Research: National Institutes of Health, Merck, LivaNova, Novartis (Content Review)

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum of 1.50 contact hours.

The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This educational activity is accredited for up to 1.50 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-24-009-L01-P (live attendance only); JA4008267-0000-24-010-H01-P (ondemand/home study).